Kinesin-like protein KIF18A inhibitors have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent and are described as potentially useful for the treatment of atopic dermatitis, autoimmune disease, cancer, Crohn’s disease, psoriasis and ulcerative colitis.

Baylor College of Medicine has disclosed new neurotrophic receptor tyrosine kinase (NTRK) inhibitors that are reported to be useful for the treatment of cancer, endometriosis, female infertility, pelvic pain and inflammatory disorders.

In a recent study, scientists from Medical University of South Carolina aimed to evaluate whether immunogenic cell death (ICD) can trigger resistance to anticancer therapies and explore potential therapeutic opportunities to revive ICD and restore drug sensitivity.

Pulmonary arterial hypertension (PAH) is a severe condition characterized by vasoconstriction and remodeling of the small pulmonary arteries, driven by a complement-dependent activation of macrophages, for which an effective treatment is lacking. Chinese researchers have investigated the potential of a complement C3 inhibitor polypeptide, CP40-KK, as an approach for treating PAH. To do this, they used a model in which PAH was induced in rats by monocrotaline.